⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 21, 2018European Journal of CancerOpen Access

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

ClinicalTrials.gov, Identifier NCT00909025.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Şahin et al. (2018) studied this question.

synapsesocial.com/papers/69d88d6ad2f7327e70ae35da https://doi.org/10.1016/j.ejca.2018.05.007

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyOriginal Research · 2019 · 251 citations
2Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published StudiesMeta-Analysis · 2014 · 71 citations
3Monoclonal antibodies for treating gastric cancer: promises and pitfallsPrognostic Study · 2016 · 9 citations